TSG-6 as a biomarker to predict efficacy of human mesenchymal stem/progenitor cells (hMSCs) in modulating sterile inflammation in vivo

Ryang Hwa Lee, Ji Min Yu, Andrea M. Foskett, Grant Peltier, John C. Reneau, Nikolay Bazhanov, Joo Youn Oh, Darwin J. Prockop

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Human mesenchymal stem/progenitor cells (hMSCs) from bone marrow and other tissues are currently being administered to large numbers of patients even though there are no biomarkers that accurately predict their efficacy in vivo. Using a mouse model of chemical injury of the cornea, we found that bone-marrow-derived hMSCs isolated from different donors varied widely in their efficacy in modulating sterile inflammation. Importantly, RT-PCR assays of hMSCs for the inflammation-modulating protein TSG-6 expressed by the TNFα-stimulated gene 6 (TSG-6 or TNFAIP6) predicted their efficacy in sterile inflammation models for corneal injury, sterile peritonitis, and bleomycin-induced lung injury. In contrast, the levels of TSG-6 mRNA were negatively correlated with their potential for osteogenic differentiation in vitro and poorly correlated with other criteria for evaluating hMSCs. Also, a survey of a small cohort suggested that hMSCs from female donors compared with male donors more effectively suppressed sterile inflammation, expressed higher levels of TSG-6, and had slightly less osteogenic potential.

Original languageEnglish (US)
Pages (from-to)16766-16771
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume111
Issue number47
DOIs
StatePublished - Nov 25 2014
Externally publishedYes

Fingerprint

Mesenchymal Stromal Cells
Biomarkers
Inflammation
Tissue Donors
Bone Marrow
Chemical Models
Bleomycin
Lung Injury
Peritonitis
Polymerase Chain Reaction
Messenger RNA

Keywords

  • Gender
  • MPO
  • Myeloperoxidase
  • Neutrophils

ASJC Scopus subject areas

  • General
  • Medicine(all)

Cite this

TSG-6 as a biomarker to predict efficacy of human mesenchymal stem/progenitor cells (hMSCs) in modulating sterile inflammation in vivo. / Lee, Ryang Hwa; Yu, Ji Min; Foskett, Andrea M.; Peltier, Grant; Reneau, John C.; Bazhanov, Nikolay; Oh, Joo Youn; Prockop, Darwin J.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, No. 47, 25.11.2014, p. 16766-16771.

Research output: Contribution to journalArticle

Lee, Ryang Hwa ; Yu, Ji Min ; Foskett, Andrea M. ; Peltier, Grant ; Reneau, John C. ; Bazhanov, Nikolay ; Oh, Joo Youn ; Prockop, Darwin J. / TSG-6 as a biomarker to predict efficacy of human mesenchymal stem/progenitor cells (hMSCs) in modulating sterile inflammation in vivo. In: Proceedings of the National Academy of Sciences of the United States of America. 2014 ; Vol. 111, No. 47. pp. 16766-16771.
@article{12182c37068042bd9e32c51ac3ca184e,
title = "TSG-6 as a biomarker to predict efficacy of human mesenchymal stem/progenitor cells (hMSCs) in modulating sterile inflammation in vivo",
abstract = "Human mesenchymal stem/progenitor cells (hMSCs) from bone marrow and other tissues are currently being administered to large numbers of patients even though there are no biomarkers that accurately predict their efficacy in vivo. Using a mouse model of chemical injury of the cornea, we found that bone-marrow-derived hMSCs isolated from different donors varied widely in their efficacy in modulating sterile inflammation. Importantly, RT-PCR assays of hMSCs for the inflammation-modulating protein TSG-6 expressed by the TNFα-stimulated gene 6 (TSG-6 or TNFAIP6) predicted their efficacy in sterile inflammation models for corneal injury, sterile peritonitis, and bleomycin-induced lung injury. In contrast, the levels of TSG-6 mRNA were negatively correlated with their potential for osteogenic differentiation in vitro and poorly correlated with other criteria for evaluating hMSCs. Also, a survey of a small cohort suggested that hMSCs from female donors compared with male donors more effectively suppressed sterile inflammation, expressed higher levels of TSG-6, and had slightly less osteogenic potential.",
keywords = "Gender, MPO, Myeloperoxidase, Neutrophils",
author = "Lee, {Ryang Hwa} and Yu, {Ji Min} and Foskett, {Andrea M.} and Grant Peltier and Reneau, {John C.} and Nikolay Bazhanov and Oh, {Joo Youn} and Prockop, {Darwin J.}",
year = "2014",
month = "11",
day = "25",
doi = "10.1073/pnas.1416121111",
language = "English (US)",
volume = "111",
pages = "16766--16771",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "47",

}

TY - JOUR

T1 - TSG-6 as a biomarker to predict efficacy of human mesenchymal stem/progenitor cells (hMSCs) in modulating sterile inflammation in vivo

AU - Lee, Ryang Hwa

AU - Yu, Ji Min

AU - Foskett, Andrea M.

AU - Peltier, Grant

AU - Reneau, John C.

AU - Bazhanov, Nikolay

AU - Oh, Joo Youn

AU - Prockop, Darwin J.

PY - 2014/11/25

Y1 - 2014/11/25

N2 - Human mesenchymal stem/progenitor cells (hMSCs) from bone marrow and other tissues are currently being administered to large numbers of patients even though there are no biomarkers that accurately predict their efficacy in vivo. Using a mouse model of chemical injury of the cornea, we found that bone-marrow-derived hMSCs isolated from different donors varied widely in their efficacy in modulating sterile inflammation. Importantly, RT-PCR assays of hMSCs for the inflammation-modulating protein TSG-6 expressed by the TNFα-stimulated gene 6 (TSG-6 or TNFAIP6) predicted their efficacy in sterile inflammation models for corneal injury, sterile peritonitis, and bleomycin-induced lung injury. In contrast, the levels of TSG-6 mRNA were negatively correlated with their potential for osteogenic differentiation in vitro and poorly correlated with other criteria for evaluating hMSCs. Also, a survey of a small cohort suggested that hMSCs from female donors compared with male donors more effectively suppressed sterile inflammation, expressed higher levels of TSG-6, and had slightly less osteogenic potential.

AB - Human mesenchymal stem/progenitor cells (hMSCs) from bone marrow and other tissues are currently being administered to large numbers of patients even though there are no biomarkers that accurately predict their efficacy in vivo. Using a mouse model of chemical injury of the cornea, we found that bone-marrow-derived hMSCs isolated from different donors varied widely in their efficacy in modulating sterile inflammation. Importantly, RT-PCR assays of hMSCs for the inflammation-modulating protein TSG-6 expressed by the TNFα-stimulated gene 6 (TSG-6 or TNFAIP6) predicted their efficacy in sterile inflammation models for corneal injury, sterile peritonitis, and bleomycin-induced lung injury. In contrast, the levels of TSG-6 mRNA were negatively correlated with their potential for osteogenic differentiation in vitro and poorly correlated with other criteria for evaluating hMSCs. Also, a survey of a small cohort suggested that hMSCs from female donors compared with male donors more effectively suppressed sterile inflammation, expressed higher levels of TSG-6, and had slightly less osteogenic potential.

KW - Gender

KW - MPO

KW - Myeloperoxidase

KW - Neutrophils

UR - http://www.scopus.com/inward/record.url?scp=84912544109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912544109&partnerID=8YFLogxK

U2 - 10.1073/pnas.1416121111

DO - 10.1073/pnas.1416121111

M3 - Article

C2 - 25385603

AN - SCOPUS:84912544109

VL - 111

SP - 16766

EP - 16771

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 47

ER -